Dr. Glenn Prestwich is a distinguished scientist and entrepreneur with extensive expertise in chemical and life sciences, currently serving as the founder of Clear Solutions Biomedical LLC. He previously held significant leadership positions including Director of the NY State Center for Advanced Technology in Medical Biotechnology (1992-1996), Director of the Center for Cell Signaling (1997-2002), and Director of the Center for Therapeutic Biomaterials (2004-2016), all recognized as Utah Centers of Excellence. With over 45 years of experience as a professor, entrepreneur, and biotech startup executive, his career has been defined by bridging academic research with practical applications in the biomedical field. His consulting company provides specialized services to numerous biotechnology firms, intellectual property attorneys, and research institutions, establishing him as a leading authority in his domain.
Dr. Prestwich's groundbreaking research encompasses the chemical biology of phosphoinositide and lysophosphatidic acid signaling, alongside pioneering work in hyaluronic acid chemistry that has led to numerous therapeutic applications. He has authored over 650 publications with an impressive H-index of 94 and is an inventor on more than 90 patents and patent applications, including 40-49 issued patents. His patented innovations span anti-cancer drugs, hyaluronan gels for wound repair and regenerative medicine, metabolically-activated insect control agents, and novel insect mating disruption technologies that have transformed integrated pest management approaches. These contributions have established him as a prolific inventor whose work continues to influence both academic research and commercial product development across multiple sectors.
Beyond his research achievements, Dr. Prestwich has co-founded nine biotechnology companies including Echelon Biosciences, Sentrx Surgical, Glycosan BioSystems, and Deuteria Biomaterials, demonstrating his exceptional ability to translate scientific discoveries into commercial ventures. He has mentored more than 125 postgraduate scientists throughout his career, shaping the next generation of researchers in chemical and life sciences. As an expert witness in intellectual property law cases since 2007, he applies his deep scientific knowledge to patent litigation involving medical devices, diagnostic tests, and pharmaceutical compositions. His ongoing work continues to advance the fields of chemical biology and biomaterials, with his consulting firm remaining at the forefront of intellectual property strategy and scientific innovation in the biomedical sector.
